Item 1. | |
(a) | Name of issuer:
Avalo Therapeutics, Inc. |
(b) | Address of issuer's principal executive
offices:
540 Gaither Road Suite 401 Rockville, MD 20850 |
Item 2. | |
(a) | Name of person filing:
Affinity Healthcare Fund, LP
Affinity Asset Advisors, LLC |
(b) | Address or principal business office or, if
none, residence:
767 Third Avenue
New York, NY 10017 |
(c) | Citizenship:
Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC - Delaware |
(d) | Title of class of securities:
Common Stock, par value $0.001 per share |
(e) | CUSIP No.:
05338F306 |
Item 3. | If this statement is filed pursuant to §§
240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
(a) | Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
(b) | Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
(c) | Insurance
company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
(d) | Investment
company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
(e) | An
investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); |
(f) | An
employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |
(g) | A
parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
(h) | A
savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813); |
(i) | A
church plan that is excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
(j) | A
non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S.
institution in accordance with § 240.13d-1(b)(1)(ii)(J), please
specify the type of institution: |
(k) | Group,
in accordance with Rule 240.13d-1(b)(1)(ii)(K). |
| |
Item 4. | Ownership |
(a) | Amount beneficially owned:
Affinity Asset Advisors, LLC (the "Advisor") is the investment manager of Affinity Healthcare Fund, LP (the "Fund") and exercises investment discretion with regard to the securities reported herein. As of December 31, 2024, the Fund beneficially owned an aggregate of 550,765 shares of Common Stock of the Issuer, or 5.3% of the outstanding shares of Common Stock of the Issuer, and the Advisor may be deemed to be the beneficial owner of such 550,765 shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of 550,765 shares of Common Stock of the Issuer. |
(b) | Percent of class:
The percentage set forth in the preceding paragraph and in Row 11 of the cover page for each reporting person is based on 10,393,954 shares of Common Stock of the Issuer outstanding as of November 6, 2024 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024. % |
(c) | Number of shares as to which the person has:
|
| (i) Sole power to vote or to direct the vote:
0
|
| (ii) Shared power to vote or to direct the
vote:
550,765
|
| (iii) Sole power to dispose or to direct the
disposition of:
0
|
| (iv) Shared power to dispose or to direct the
disposition of:
550,765
|
Item 5. | Ownership of 5 Percent or Less of a Class. |
| |
Item 6. | Ownership of more than 5 Percent on Behalf of
Another Person. |
|
Not Applicable
|
Item 7. | Identification and Classification of the
Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or
Control Person. |
|
Not Applicable
|
Item 8. | Identification and Classification of Members of
the Group. |
|
Not Applicable
|
Item 9. | Notice of Dissolution of Group. |
|
Not Applicable
|